Airovent 10 mg N28 Tablet

Ayrovent, 10 mq coated tablets

Ayrovent composition

Active ingredient: 10.39 mg sodium montelukast equivalent to 10 mg montelukast in 1 tablet

Contraindications

High sensitivity to any of the components of the medicinal product.

Use during pregnancy and lactation

Experimental studies show that the medicinal substance has no negative effect on pregnancy or on embryo/fetal development.
In clinical studies where the medicinal substance was administered during pregnancy, it was not noted that it causes malformations (e.g., limb defect).
Montelukast during pregnancy may be prescribed only when its use is necessary.
According to experimental studies, montelukast is excreted in breast milk. No clinical studies have been conducted on whether montelukast is excreted in human breast milk. Montelukast during lactation may be prescribed only when its use is necessary.

Directions for use and dosage

Adolescents aged 15 years and older and adults suffering from asthma and seasonal allergic rhinitis should take one Airovent 10 mg coated tablet every evening as the daily dose.
General advice. The therapeutic effect of treatment according to parameters that ensure control of asthma attacks occurs within one day. Montelukast can be taken during meals or on an empty stomach. Patients should take montelukast not only during periods when asthma worsens, but also when asthma control is ensured.
Airovent 10 mg coated tablets should not be used together with medicinal products containing the active ingredient montelukast.
In elderly patients suffering from renal impairment, as well as in patients with mild or moderate hepatic impairment, it is not necessary to adjust the dose. There is no information regarding the use of the medicinal product in patients with severe hepatic impairment. Dosages are the same for male and female patients.
Use in combination with other anti-asthma medicinal substances
Airovent 10 mg coated tablets may be used as an additional agent in the treatment carried out with asthma anti-inflammatory corticosteroid inhalations prescribed for the patient, and when short-acting B-agonists cannot provide clinical monitoring/control for the patients. When treatment with montelukast is replaced by corticosteroid inhalation, the intake of the prepart should be discontinued gradually.